Citations (6)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Antonio Tursi, Giammarco Mocci, Leonardo Allegretta, Giovanni Aragona, Maria Antonia Bianco, Raffaele Colucci, Antonio Cuomo, Nicola Della Valle, Antonio Ferronato, Giacomo Forti, Federica Gaiani, Maria Giovanna Graziani, Roberto Lorenzetti, Francesco Luzza, Pietro Paese, Antonio Penna, Roberta Pica, Giuseppe Pranzo, Stefano Rodinò, Antonella Scarcelli, Costantino Zampaletta, Lorenzo Brozzi, Clelia Cicerone, Andrea Cocco, Gianluigi De’ Angelis, Laura Donnarumma, Serafina Fiorella, Chiara Iannelli, Tiziana Larussa, Marco Le Grazie, Ileana Luppino, Costantino Meucci, Roberto FaggianI, Cristiano Pagnini, Patrizia Perazzo, Kryssia Isabel Rodriguez-Castro, Rodolfo Sacco, Ladislava Sebkova, Mariaelena Serio, Alberta De Monti, Marcello Picchio, Daniele Napolitano, Elisa Schiavoni, Laura Turchini, Franco Scaldaferri, Daniela Pugliese, Luisa Guidi, Lucrezia Laterza, Giuseppe Privitera, Marco Pizzoferrato, Loris R. Lopetuso, Alessandro Armuzzi, Walter Elisei, Giovanni Maconi & Alfredo Papa. (2022) Comparison of performances of infliximab biosimilars CT-P13 versus SB2 in the treatment of inflammatory bowel diseases: a real-life multicenter, observational study in Italy. Expert Opinion on Biological Therapy 22:2, pages 313-320.
Read now
Read now
Articles from other publishers (5)
Karim Sariahmed, Joshua Kurian, Anjani K. Singh, Christopher Leyton, Aurelia Minuti, Elina Jerschow, Shitij Arora & Sunit P. Jariwala. (2022) Social, political, and economic determinants of access to biologics: A scoping review of structural determinants in the clinical disparities literature. Research in Social and Administrative Pharmacy 18:12, pages 4038-4047.
Crossref
Crossref
Giammarco Mocci, Giorgia Bodini, Leonardo Allegretta, Alessia Immacolata Cazzato, Stefania Chiri, Giovanni Aragona, Patrizia Perazzo, Antonio Ferronato, Maria Giovanna Graziani, Cristiano Pagnini, Costantino Zampaletta, Camilla Graziosi, Marcello Picchio, Walter Elisei, Giovanni Maconi & Antonio Tursi. (2022) Adalimumab Biosimilar GP2017 versus Adalimumab Originator in Treating Patients with Inflammatory Bowel Diseases: A Real-Life, Multicenter, Observational Study. Biomedicines 10:8, pages 1799.
Crossref
Crossref
Marieke J Pierik, Andrea E van der Meulen, Klaas Van der Linde, Maurice Lutgens, Johan P Kuijvenhoven, Halil Akol, Ids J Klompmaker, Michelle S G Sikkens, Yvonne J B van Megen, Corinne M Stoop, Joanne P J Bloemsaat-Minekus & Gerard Dijkstra. (2022) Switching From Reference Infliximab to Biosimilar CT-P13 Did Not Change Quality of Life in Stable Inflammatory Bowel Disease Patients. Crohn's & Colitis 360 4:3.
Crossref
Crossref
Guanglin Cui, Jon Florholmen & Rasmus Goll. (2022) Could Mucosal TNF Transcript as a Biomarker Candidate Help Optimize Anti-TNF Biological Therapy in Patients With Ulcerative Colitis?. Frontiers in Immunology 13.
Crossref
Crossref
Yun-Seong Kang, Hyoung Ho Moon, Seung Eun Lee, Yun Jeong Lim & Hyoun Woo Kang. (2014) Clinical Experience of the Use of CT-P13, a Biosimilar to Infliximab in Patients with Inflammatory Bowel Disease: A Case Series. Digestive Diseases and Sciences 60:4, pages 951-956.
Crossref
Crossref